Eli
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
BioAge Labs Files for $100 Million IPO to Advance Obesity Treatment Candidate Azelaprag
BioAge Labs, IPO, Obesity Treatment, Azelaprag, Eli Lilly, Novo Nordisk, Clinical Trials
Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss
Eli Lilly, Zepbound, weight loss medication, direct-to-consumer sales, affordable pricing, obesity treatment
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound
Eli Lilly Unveils State-of-the-Art Genetic Medicine Research Center in Boston
Eli Lilly, Boston, genetic medicines, research center, innovation hub, biotech
Eli Lilly’s Mounjaro and Zepbound Return to Stock After Extended Shortage, FDA Announces
Eli Lilly, Mounjaro, Zepbound, FDA, drug shortage, weight loss medication, diabetes medication
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition
, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,
Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns
Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy